Nephrology News
Drug Combo Promising for HCV Infection in Patients With Advanced CKD
Researchers report a high rate of sustained virologic response after 12 weeks of treatment with a ribavirin-free co-formulation of glecaprevir and pibrentasvir.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/